The Anti-Inflammatory
Lysine-Proline-Valine (alpha-MSH fragment)
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (alpha-MSH). Despite being only three amino acids long, KPV retains the potent anti-inflammatory properties of the parent hormone without its pigmentation effects. It has shown particular promise for inflammatory bowel disease, skin inflammation, and antimicrobial applications.
KPV exerts its anti-inflammatory effects by inhibiting NF-kB activation and modulating inflammatory cytokine production. It can enter cells and directly interact with intracellular inflammatory signaling pathways.
Inhibits NF-kB nuclear translocation, preventing the activation of the master inflammatory transcription factor and reducing production of pro-inflammatory mediators.
Suppresses production of TNF-alpha, IL-6, IL-1beta, and other pro-inflammatory cytokines by activated immune cells.
Penetrates cell membranes due to its small size, allowing direct intracellular anti-inflammatory action beyond receptor-mediated effects.
Demonstrates antimicrobial properties against Staphylococcus aureus and Candida species, providing dual anti-inflammatory and anti-infective benefits.
Research demonstrates significant reduction in inflammatory markers through NF-kB inhibition, with effects comparable to or exceeding traditional anti-inflammatory agents in preclinical models.
Particularly promising for inflammatory bowel conditions, with preclinical evidence showing reduced colonic inflammation and improved mucosal healing.
Shows potential for inflammatory skin conditions through both anti-inflammatory and antimicrobial actions at the skin level.
Direct antimicrobial activity against common pathogens provides additional therapeutic value beyond inflammation reduction.
KPV significantly reduced colonic inflammation in experimental colitis models, with effects comparable to established anti-inflammatory treatments and improved mucosal healing.
Oral administration of KPV-loaded nanoparticles demonstrated targeted delivery to inflamed intestinal tissue with significant reduction in inflammatory markers.
KPV demonstrated antimicrobial activity against S. aureus and C. albicans through direct membrane disruption and intracellular mechanisms.
KPV is derived from a naturally occurring hormone fragment and has shown a favorable safety profile in preclinical studies. Its small tripeptide structure is rapidly metabolized into naturally occurring amino acids. Human clinical trial data is still limited.
Research Status
KPV has promising preclinical data, particularly for inflammatory bowel conditions and skin inflammation. Human clinical trials are in early stages. The compound benefits from the extensive research on its parent molecule, alpha-MSH.
Regulatory Note
KPV is not FDA-approved. Available as a research compound through select compounding pharmacies. Its regulatory pathway is still being defined.